{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:03:41Z","timestamp":1793901821592,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"26","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2022,6,24]]},"DOI":"10.1038\/s41388-022-02350-6","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T12:04:12Z","timestamp":1653566652000},"page":"3455-3460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets"],"prefix":"10.1038","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-4043","authenticated-orcid":false,"given":"Alberto","family":"Puccini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Poorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8529-7824","authenticated-orcid":false,"given":"Andreas","family":"Seeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony F.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Battaglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuma","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Naseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Michael","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-9568","authenticated-orcid":false,"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"2350_CR1","unstructured":"Lauwers G, Carneiro F, Graham D, Curado M, Franceschi S. Classification of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010. pp. 48\u201358."},{"key":"2350_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ijc.28981","volume":"136","author":"N Hugen","year":"2015","unstructured":"Hugen N, Verhoeven RH, Lemmens VE, van Aart CJ, Elferink MA, Radema SA, et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. Int J Cancer. 2015;136:333\u20139.","journal-title":"Int J Cancer"},{"key":"2350_CR3","doi-asserted-by":"publisher","first-page":"e0176637","DOI":"10.1371\/journal.pone.0176637","volume":"12","author":"L Chen","year":"2017","unstructured":"Chen L, Liu X, Gao L, Wang R, Gao D, Bai D. The clinicopathological features and prognosis of signet ring cell carcinoma of the esophagus: a 10-year retrospective study in China. PLoS One. 2017;12:e0176637.","journal-title":"PLoS One"},{"key":"2350_CR4","doi-asserted-by":"publisher","first-page":"e0162088","DOI":"10.1371\/journal.pone.0162088","volume":"11","author":"X Wu","year":"2016","unstructured":"Wu X, Zhang Z, Li X, Lin Q, Chen G, Lu J, et al. Poorer prognosis of primary signet-ring cell carcinoma of the breast compared with mucinous carcinoma. PLoS One. 2016;11:e0162088.","journal-title":"PLoS One"},{"key":"2350_CR5","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.4065\/mcp.2010.0463","volume":"85","author":"JN Warner","year":"2010","unstructured":"Warner JN, Nakamura LY, Pacelli A, Humphreys MR, Castle EP. Primary signet ring cell carcinoma of the prostate. Mayo Clin Proc. 2010;85:1130\u20136.","journal-title":"Mayo Clin Proc"},{"key":"2350_CR6","doi-asserted-by":"crossref","unstructured":"Benesch MGK, Mathieson A. Epidemiology of signet ring cell adenocarcinomas. Cancers. 2020;12:1544.","DOI":"10.3390\/cancers12061544"},{"key":"2350_CR7","unstructured":"Bosman FT, Carneiro F, Hruban RH, Theise ND WHO Classification of Tumours of the Digestive System. World Health Organization; Geneva, Switzerland: 2010."},{"key":"2350_CR8","unstructured":"WHO Digestive System Tumours, WHO Classification of Tumours Series. 5th ed. International Agency for Research on Cancer; Lyon, France: 2019."},{"key":"2350_CR9","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1245\/s10434-013-3466-8","volume":"21","author":"ZM Bamboat","year":"2014","unstructured":"Bamboat ZM, Tang LH, Vinuela E, Kuk D, Gonen M, Shah MA, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol. 2014;21:1678\u201385.","journal-title":"Ann Surg Oncol"},{"key":"2350_CR10","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1200\/JCO.2012.42.6635","volume":"30","author":"S Taghavi","year":"2012","unstructured":"Taghavi S, Jayarajan SN, Davey A, Willis AI. Prognostic significance of signet ring gastric cancer. J Clin Oncol. 2012;30:3493\u20138.","journal-title":"J Clin Oncol"},{"key":"2350_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5858\/2004-128-765-DTITIA","volume":"128","author":"DE Henson","year":"2004","unstructured":"Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765\u201370.","journal-title":"Arch Pathol Lab Med"},{"key":"2350_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10120-013-0234-1","volume":"17","author":"KJ Kwon","year":"2014","unstructured":"Kwon KJ, Shim KN, Song EM, Choi JY, Kim SE, Jung HK, et al. Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Gastric Cancer. 2014;17:43\u201353.","journal-title":"Gastric Cancer"},{"key":"2350_CR13","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.3748\/wjg.v21.i40.11428","volume":"21","author":"S Pernot","year":"2015","unstructured":"Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21:11428\u201338.","journal-title":"World J Gastroenterol"},{"key":"2350_CR14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/SLA.0000000000001793","volume":"265","author":"HJ Chon","year":"2017","unstructured":"Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, et al. Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Ann Surg. 2017;265:946\u201353.","journal-title":"Ann Surg"},{"key":"2350_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/srep26313","volume":"6","author":"P Kong","year":"2016","unstructured":"Kong P, Wu R, Yang C, Geng Q, Liu J, Chen S, et al. Prognostic impact of the signet ring cell type in node-negative gastric cancer. Sci Rep. 2016;6:26313.","journal-title":"Sci Rep."},{"key":"2350_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41416-019-0548-9","volume":"121","author":"K Korphaisarn","year":"2019","unstructured":"Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, et al. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019;121:505\u201310.","journal-title":"Br J Cancer"},{"key":"2350_CR17","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1245\/s10434-012-2321-7","volume":"19","author":"JR Hyngstrom","year":"2012","unstructured":"Hyngstrom JR, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the national cancer data base. Ann Surg Oncol. 2012;19:2814\u201321.","journal-title":"Ann Surg Oncol"},{"key":"2350_CR18","first-page":"2195","volume":"91","author":"SY Tung","year":"1996","unstructured":"Tung SY, Wu CS, Chen PC. Primary signet ring cell carcinoma of colorectum: an age- and sex-matched controlled study. Am J Gastroenterol. 1996;91:2195\u20139.","journal-title":"Am J Gastroenterol"},{"key":"2350_CR19","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s00432-016-2224-2","volume":"142","author":"U Nitsche","year":"2016","unstructured":"Nitsche U, Friess H, Agha A, Angele M, Eckel R, Heitland W, et al. Prognosis of mucinous and signet-ring cell colorectal cancer in a population-based cohort. J Cancer Res Clin Oncol. 2016;142:2357\u201366.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2350_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1634\/theoncologist.2018-0117","volume":"24","author":"A Puccini","year":"2019","unstructured":"Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, et al. Impact of patient age on molecular alterations of left-sided colorectal tumors. Oncologist. 2019;24:319\u201326.","journal-title":"Oncologist"},{"key":"2350_CR21","first-page":"3817","volume":"37","author":"K Tajiri","year":"2017","unstructured":"Tajiri K, Sudou T, Fujita F, Hisaka T, Kinugasa T, Akagi Y. Clinicopathological and corresponding genetic features of colorectal signet ring cell carcinoma. Anticancer Res. 2017;37:3817\u201323.","journal-title":"Anticancer Res"},{"key":"2350_CR22","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1245\/s10434-014-4159-7","volume":"22","author":"K Inamura","year":"2015","unstructured":"Inamura K, Yamauchi M, Nishihara R, Kim SA, Mima K, Sukawa Y, et al. Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol. 2015;22:1226\u201335.","journal-title":"Ann Surg Oncol"},{"key":"2350_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/SLA.0b013e3182a69f7e","volume":"258","author":"U Nitsche","year":"2013","unstructured":"Nitsche U, Zimmermann A, Spath C, Muller T, Maak M, Schuster T, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg. 2013;258:775\u201382. discussion 782\u2013773","journal-title":"Ann Surg"},{"key":"2350_CR24","doi-asserted-by":"crossref","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182\u20138.","DOI":"10.1111\/his.13975"},{"key":"2350_CR25","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/SLA.0b013e3181b21c7b","volume":"250","author":"G Piessen","year":"2009","unstructured":"Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250:878\u201387.","journal-title":"Ann Surg"},{"key":"2350_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-018-0868-0","volume":"22","author":"C Mariette","year":"2019","unstructured":"Mariette C, Carneiro F, Grabsch HI, van der Post RS, Allum W, de Manzoni G, et al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22:1\u20139.","journal-title":"Gastric Cancer"},{"key":"2350_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/bjc.2017.168","volume":"117","author":"MA Alvi","year":"2017","unstructured":"Alvi MA, Loughrey MB, Dunne P, McQuaid S, Turkington R, Fuchs MA, et al. Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. Br J Cancer. 2017;117:203\u20139.","journal-title":"Br J Cancer"},{"key":"2350_CR28","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2217\/fon-2020-0242","volume":"16","author":"V Barresi","year":"2020","unstructured":"Barresi V, Pedrazzani C. Colorectal signet ring cell carcinoma: advancing research in a rare cancer. Future Oncol. 2020;16:1161\u20133.","journal-title":"Future Oncol"},{"key":"2350_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","volume":"33","author":"R Yaeger","year":"2018","unstructured":"Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33:125\u201336 e123.","journal-title":"Cancer Cell"},{"key":"2350_CR30","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"N Atlas","year":"2012","unstructured":"Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330\u20137. Cancer Genome","journal-title":"Nature"},{"key":"2350_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.amjsurg.2006.12.041","volume":"194","author":"WS Lee","year":"2007","unstructured":"Lee WS, Chun HK, Lee WY, Yun SH, Cho YB, Yun HR, et al. Treatment outcomes in patients with signet ring cell carcinoma of the colorectum. Am J Surg. 2007;194:294\u20138.","journal-title":"Am J Surg"},{"key":"2350_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10350-007-9073-7","volume":"51","author":"R Pande","year":"2008","unstructured":"Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, et al. Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum. 2008;51:50\u201355.","journal-title":"Dis Colon Rectum"},{"key":"2350_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70985-0","volume":"10","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Yan N, Pan S, Wang DW, Li ZW. The value of adjuvant chemotherapy in stage II\/III colorectal signet ring cell carcinoma. Sci Rep. 2020;10:14126.","journal-title":"Sci Rep."},{"key":"2350_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13304-018-0550-4","volume":"70","author":"V Mengardo","year":"2018","unstructured":"Mengardo V, Treppiedi E, Bencivenga M, Dal Cero M, Giacopuzzi S. Tailored treatment for signet ring cell gastric cancer. Updates Surg. 2018;70:167\u201371.","journal-title":"Updates Surg"},{"key":"2350_CR35","doi-asserted-by":"crossref","first-page":"153303382096074","DOI":"10.1177\/1533033820960746","volume":"19","author":"H Gong","year":"2020","unstructured":"Gong H, Chu Y, Hu Q, Song Q. Preoperative radiotherapy is associated with significant survival benefits for patients with gastric signet ring cell carcinoma: a SEER-based approach. Technol Cancer Res Treat. 2020;19:1533033820960746.","journal-title":"Technol Cancer Res Treat"},{"key":"2350_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-015-0148-y","volume":"8","author":"S Kim","year":"2015","unstructured":"Kim S, Fiteni F, Paget-Bailly S, Ghiringhelli F, Lakkis Z, Jary M, et al. The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas. J Hematol Oncol. 2015;8:52.","journal-title":"J Hematol Oncol"},{"key":"2350_CR37","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318.","journal-title":"N Engl J Med"},{"key":"2350_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1\u201310.","journal-title":"J Clin Oncol"},{"key":"2350_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s12276-021-00559-1","volume":"53","author":"MG Noh","year":"2021","unstructured":"Noh MG, Yoon Y, Kim G, Kim H, Lee E, Kim Y, et al. Practical prediction model of the clinical response to programmed death-ligand 1 inhibitors in advanced gastric cancer. Exp Mol Med. 2021;53:223\u201334.","journal-title":"Exp Mol Med"},{"key":"2350_CR40","doi-asserted-by":"publisher","first-page":"38850","DOI":"10.18632\/oncotarget.16407","volume":"8","author":"S Jin","year":"2017","unstructured":"Jin S, Xu B, Yu L, Fu Y, Wu H, Fan X, et al. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. Oncotarget. 2017;8:38850\u201362.","journal-title":"Oncotarget"},{"key":"2350_CR41","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.annonc.2020.05.027","volume":"31","author":"G Mauri","year":"2020","unstructured":"Mauri G, Arena S, Siena S, Bardelli A, Sartore-Bianchi A. The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Ann Oncol. 2020;31:1135\u201347.","journal-title":"Ann Oncol"},{"key":"2350_CR42","doi-asserted-by":"publisher","first-page":"662055","DOI":"10.3389\/fonc.2021.662055","volume":"11","author":"K Zimmer","year":"2021","unstructured":"Zimmer K, Kocher F, Puccini A, Seeber A. Targeting BRCA and DNA damage repair genes in GI cancers: pathophysiology and clinical perspectives. Front Oncol. 2021;11:662055.","journal-title":"Front Oncol"},{"key":"2350_CR43","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/cancers14061388","volume":"14","author":"F Catalano","year":"2022","unstructured":"Catalano F, Borea R, Puglisi S, Boutros A, Gandini A, Cremante M, et al. Targeting the DNA damage response pathway as a novel therapeutic strategy in colorectal cancer. Cancers. 2022;14:1388.","journal-title":"Cancers"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02350-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02350-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02350-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T14:04:08Z","timestamp":1656079448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-022-02350-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":43,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2022,6,24]]}},"alternative-id":["2350"],"URL":"https:\/\/doi.org\/10.1038\/s41388-022-02350-6","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KP and WMK are employed by Caris Life Sciences. JLM and AS are consultants for Caris Life Sciences. AFS and RMG received research and travel support from Caris Life Sciences. MES and H-JL received travel support from Caris Life Sciences. AP, FC, FB, MDB, RT, MN, WZ, and PAP declare that there are no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All human subjects\u2019 data were de-identified prior to analysis. Thus, this research was determined to be exempt from the requirement for informed consent per the Western Institutional Review Board (WIRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}